Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Non-small Cell Lung Cancer
Interventions: Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Detroit, Michigan • Reno, Nevada

Conditions: Nicotine Vaping, Nicotine, Vaping
Interventions: CA35, CM35, Cig; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 24 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Dermatomyositis, Polymyositis
Interventions: Infliximab; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Immediate Post-Treatment Care, Aging Mid-Face, Aging
Interventions: ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).; Other
Lead sponsor: Lynch Regenerative Medicine; Network
Eligibility: 40 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Nashville, Tennessee

Conditions: Pancreatic Cancer, Malnutrition
Interventions: Ensure Max Protein; Dietary Supplement
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sickle Cell Disease
Interventions: Eptifibatide, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx, Squamous Cell Carcinoma
Interventions: Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Early Rheumatoid Arthritis
Interventions: Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo; Biological · Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 31
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more

Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801; Drug
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
Interventions: PLAFOND diet; Dietary Supplement
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Orange, California • Torrance, California

Conditions: Muscular Dystrophy, Duchenne
Interventions: MNK-1411, Placebo; Drug · Other
Lead sponsor: Mallinckrodt ARD LLC; Industry
Eligibility: 4 Years to 8 Years · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Gulf Breeze, Florida • Atlanta, Georgia • Nashville, Tennessee + 2 more

Conditions: Painful Lumbar Radiculopathy, Sciatica, Radiculopathy
Interventions: BG00010, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 25
States / cities: Phoenix, Arizona • Fresno, California • Lomita, California + 22 more

Conditions: Major Depression, Bipolar Disorder, Unipolar Depression
Interventions: triiodothyronine, sertraline; Drug
Lead sponsor: Hadassah Medical Organization; Other
Eligibility: 18 Years to 70 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Spinal Cord Injury, Spasticity
Interventions: Focused extracorporeal shockwave therapy, Botulinum toxin, Sham; Device · Drug · Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Transient Insomnia
Interventions: Gabapentin, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 8
States / cities: Anaheim, California • San Diego, California • Orlando, Florida + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: Tomivosertib, Pembrolizumab, Pemetrexed; Drug · Biological
Lead sponsor: Effector Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 131
States / cities: Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more

Conditions: Degenerative Disc Disease
Interventions: Intradiscal rhGDF-5, Water for injection; Drug · Other
Lead sponsor: DePuy Spine; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 10
States / cities: Phoenix, Arizona • Santa Monica, California • Durango, Colorado + 7 more

Conditions: Prostate Cancer
Interventions: Degarelix, Leuprolide; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: Male only
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 48
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more

Conditions: Fibromyalgia
Interventions: Pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 26
States / cities: Tucson, Arizona • Orange, California • Santa Ana, California + 21 more

Conditions: Ocular Hypertension, Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 19 Years to 99 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Covid19
Interventions: Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Praliciguat (Part A), Placebo (Part A), Praliciguat (Part B); Drug · Other
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 30
States / cities: Chula Vista, California • Garden Grove, California • Los Angeles, California + 26 more

Conditions: Infection
Interventions: Hyperbaric Oxygen, Hyperbaric Air/Oxygen, Normobaric oxygen; Drug · Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions: N-acetylcysteine; Drug
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts

Search by objective public record fields.

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis

Post-market Cosmetic Evaluation of Ariessence™ Pure PDGF+ Following Ablative Laser

Whipple Protein Study

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy

Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.

Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury

A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease